Search Results
Feb 24, 2026, 16:05 ET Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
FDA approval and launched Zepzelca, in combination with atezolizumab, for first-line maintenance treatment of extensive-stage small cell lung cancer.Company expects 2026 total revenue of between $4.25 and $4.50 billion, with double-digit growth across the combined epilepsy
More news about: Jazz Pharmaceuticals plc
Feb 24, 2026, 10:58 ET Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
delivered a highly statistically significant improvement in event-free survival as adjuvant therapy in early-stage RET fusion-positive non-small cell lung cancer. The trial is the first randomized Phase 3 study to evaluate a selective RET kinase inhibitor in this population."We have consistently
More news about: USA News Group
Feb 24, 2026, 10:12 ET Olympus Announces Pediatric Use Indication for Two Single-Use Bronchoscopes
bleeding from biopsied site, or an allergic reaction to medications. Some patients may experience rare but more serious complications such as a collapsed lung, respiratory failure, heart attack, and/or cardiac arrhythmia.For information about the complete Olympus pulmonology portfolio, please visit the
More news about: Olympus Corporation of the Americas
Feb 24, 2026, 09:30 ET Lung Cancer Research Foundation Launches Small Cell Lung Cancer Grants in Collaboration with AstraZeneca
Two New Lung Cancer Research Grants Aim to Accelerate Discoveries and Enhance Outcomes in Small Cell Lung Cancer TreatmentNEW YORK, Feb. 24, 2026 /PRNewswire/ -- The Lung Cancer Research Foundation
More news about: Lung Cancer Research Foundation
Feb 24, 2026, 09:00 ET AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)
participants who have a documented history of histopathologically confirmed castrate resistant prostate cancer, colorectal cancer, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell cancer, ovarian cancer, cervical cancer, endometrial cancer, triple negative breast cancer, or esophageal
More news about: AtomVie Global Radiopharma Inc.
Feb 24, 2026, 09:00 ET AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)
participants who have a documented history of histopathologically confirmed castrate resistant prostate cancer, colorectal cancer, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell cancer, ovarian cancer, cervical cancer, endometrial cancer, triple negative breast cancer, or esophageal
More news about: AtomVie Global Radiopharma Inc.
Feb 24, 2026, 06:00 ET Brainomix Extends Series C Financing to $25.4M (£18.8M) to Support U.S. Expansion
confidence in our technology, our team, and the impact Brainomix 360 Stroke and e-Lung can have on patient care," said Dr Michalis Papadakis, CEO and co-founder of Brainomix. "Stroke care depends on speed, while lung fibrosis care requires early identification and consistent clinical decision-making
More news about: Brainomix
Feb 24, 2026, 01:44 ET Fractal Launches PiEvolve, an Evolutionary Agentic Engine for Autonomous Machine Learning and Scientific Discovery
Qure.ai, a global healthcare AI leader enhancing the rapid identification and management of tuberculosis, lung cancer, and stroke. Fractal's dedicated AI Research team is focused on foundational
More news about: Fractal Analytics Limited
Feb 24, 2026, 01:33 ET Fractal Launches PiEvolve, an Evolutionary Agentic Engine for Autonomous Machine Learning and Scientific Discovery
Qure.ai, a global healthcare AI leader enhancing the rapid identification and management of tuberculosis, lung cancer, and stroke. Fractal's dedicated AI Research team is focused on foundational
More news about: Fractal Analytics Limited
Feb 24, 2026, 01:25 ET Fractal Launches PiEvolve, an Evolutionary Agentic Engine for Autonomous Machine Learning and Scientific Discovery
Qure.ai, a global healthcare AI leader enhancing the rapid identification and management of tuberculosis, lung cancer, and stroke. Fractal's dedicated AI Research team is focused on foundational
More news about: Fractal Analytics Limited
Feb 23, 2026, 10:45 ET Extracorporeal Membrane Oxygenation Machine (ECMO) Market to Reach $793.7 Million, Globally, by 2033 at 4.6% CAGR: Allied Market Research
Growth in demand for extracorporeal membrane oxygenation (ECMO) in lung transplants. Opportunities
More news about: Allied Market Research
Feb 23, 2026, 08:55 ET Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Feb 23, 2026, 08:30 ET IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026
liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its
More news about: IceCure Medical
Feb 23, 2026, 08:00 ET Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer
portfolio, providing further protection for various therapeutic combinations, including the Acclaim-3 clinical trial for the treatment of small cell lung cancer using REQORSA in combination with PD-L1 antibodies.
More news about: Genprex, Inc.
Feb 23, 2026, 08:00 ET Dark Places Big Screen Premiere Announced & Hits TUBI, Fawesome & More - Horror Movie News
here.With the recently released popularity of IRON LUNG by influencer Markiplier, the decision was made to push DARK PLACES into more big-screen showings throughout the New England area, with the hopes of
More news about: Cinema Epoch
Feb 22, 2026, 19:10 ET CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC
sugemalimab has received a new indication approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for stage III non-small cell lung cancer (NSCLC). This marks the second indication approved for the product in the UK.This approval is based on the GEMSTONE-301 study, a multicenter,
More news about: CStone Pharmaceuticals
Feb 21, 2026, 08:00 ET TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years
STELARA®, including: headache, seizures, confusion, and vision problems.Lung InflammationCases of lung inflammation have happened in some people who receive STELARA® and may be serious. These lung problems may need to be treated in a hospital. Tell your healthcare provider right
More news about: Johnson & Johnson
Feb 20, 2026, 16:05 ET TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on February 18, 2026, TransMedics granted non-qualified stock options to purchase an aggregate of 40,089
More news about: TransMedics Group, Inc.
Feb 20, 2026, 10:00 ET ALPHA-1 FOUNDATION ENGAGES MIAMI COMMUNICATIONS FIRM TO ACCELERATE FUNDRAISING
liver, with no cure to date. Lung-affected patients typically do not show symptoms until adulthood, when their lung function declines much more rapidly than in a typically aging adult. Patients are often diagnosed with emphysema and Chronic Obstructive Pulmonary Disease (COPD). Lung-affected patients are treated
More news about: The Weinbach Group, Inc.
Feb 20, 2026, 08:00 ET Zenocutuzumab Treatment Beyond Progression Demonstrates Continued Benefit in Patients with NRG1+ Non-Small Cell Lung Cancer: New Results from the eNRGy Trial
patients with advanced neuregulin 1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC). Results were presented at the 2026 International Association for the Study of Lung Cancer (IASLC) Targeted Therapies of Lung Cancer (TTLC) meeting. NRG1+ NSCLC is associated with low response rates
More news about: Partner Therapeutics, Inc.
Feb 19, 2026, 17:00 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer
reaction occurs, permanently discontinue RYBREVANT®.Interstitial Lung Disease/Pneumonitis RYBREVANT FASPRO™ and RYBREVANT® can cause severe and fatal interstitial lung disease (ILD)/pneumonitis.RYBREVANT FASPRO™ with LAZCLUZE®In
More news about: Johnson & Johnson
Feb 19, 2026, 16:02 ET GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results
cancer2,*. The Galleri test increases the number of cancers detected seven-fold when added to recommended screening for breast, cervical, colorectal and lung cancers, and has the lowest false positive rate of any MCED test on the market1,2,3,4,**. When a cancer signal is found, Galleri provides
More news about: GRAIL, Inc.
Feb 19, 2026, 16:01 ET Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate
improvement in the overall cancer detection rate compared to standard of care screening alone in England for breast, colorectal, cervical and high risk lung cancer.Substantial increase in the absolute number of Stage I-II cancers in the 12 pre-specified deadly cancer types that are typically found
More news about: GRAIL, Inc.
Feb 19, 2026, 08:30 ET IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation
liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its
More news about: IceCure Medical
Feb 19, 2026, 08:19 ET Fractal launches Vaidya 2.0, outperforming leading frontier models on Healthcare AI Benchmarks
Qure.ai, a global healthcare AI leader enhancing the rapid identification and management of tuberculosis, lung cancer, and stroke. Fractal's dedicated AI Research team is focused on foundational
More news about: Fractal Analytics Limited